Evaluation of the prognostic significance of MSMB and CRISP3 in prostate cancer using automated image analysis

Modern Pathology

Volumn 24, Issue 5, 2011, Pages 708-719

  Dahlman, Anna ^a,b   Rexhepaj, Elton ^c   Brennan, Donal J ^c   Gallagher, William M ^c   Gaber, Alexander ^b   Lindgren, Anna ^d   Jirström, Karin ^b   Bjartell, Anders ^a,b  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c UNIVERSITY COLLEGE DUBLIN   (Ireland)

^d LUND UNIVERSITY   (Sweden)

Author keywords

outcome prediction; PSP94; tissue biomarker

Indexed keywords

BETA MICROSEMINOPROTEIN; CYSTEINE; PROTEIN CRISP3; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER RISK; CLINICAL FEATURE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; TISSUE MICROARRAY;

EID: 79955574256     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2010.238     Document Type: Article

References (47)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-249.
2. Kattan MW, Eastham JA, Stapleton AM, et al. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 1998;90:766-771. (Pubitemid 28259189)
3. Shariat SF, Karakiewicz PI, Roehrborn CG, et al. An updated catalog of prostate cancer predictive tools. Cancer 2008;113:3075-3099.
4. Fiorentino M, Capizzi E, Loda M. Blood and tissue biomarkers in prostate cancer: state of the art. Urol Clin North Am 2010;37:131-141.
5. Shariat SF, Karakiewicz PI, Suardi N, et al. Comparison of nomograms with other methods for predicting outcomes in prostate cancer: a critical analysis of the literature. Clin Cancer Res 2008;14:4400-4407.
6. Faratian D, Kay C, Robson T, et al. Automated image analysis for high-throughput quantitative detection of ER and PR expression levels in large-scale clinical studies: the TEAM Trial Experience. Histopathology 2009;55:587-593.
7. Turbin DA, Leung S, Cheang MC, et al. Automated quantitative analysis of estrogen receptor expression in breast carcinoma does not differ from expert pathologist scoring: a tissue microarray study of 3,484 cases. Breast Cancer Res Treat 2008;110:417-426. (Pubitemid 351962583)
8. Rexhepaj E, Brennan DJ, Holloway P, et al. Novel image analysis approach for quantifying expression of nuclear proteins assessed by immunohistochemistry: application to measurement of oestrogen and progesterone receptor levels in breast cancer. Breast Cancer Res 2008;10:R89.
9. Brennan DJ, Rexhepaj E, O'Brien SL, et al. Altered cytoplasmic-to-nuclear ratio of survivin is a prognostic indicator in breast cancer. Clin Cancer Res 2008;14: 2681-2689.
10. Bjartell AS, Al-Ahmadie H, Serio AM, et al. Association of cysteine-rich secretory protein 3 and beta-microseminoprotein with outcome after radical prostatectomy. Clin Cancer Res 2007;13:4130-4138. (Pubitemid 47105975)
11. Lilja H, Abrahamsson P-A. Three predominant proteins secreted by the human prostate gland. Prostate 1988;12:29-38.
12. Abrahamsson PA, Lilja H, Falkmer S, et al. Immunohis-tochemical distribution of the three predominant secretory proteins in the parenchyma of hyperplastic and neoplastic prostate glands. Prostate 1988;12:39-46.
13. Whitaker HC, Warren AY, Eeles R, et al. The potential value of microseminoprotein-beta as a prostate cancer biomarker and therapeutic target. Prostate 2010;70: 333-340.
14. Doctor VM, Sheth AR, Simha MM, et al. Studies on immunocytochemical localization of inhibin-like material in human prostatic tissue: comparison of its distribution in normal, benign and malignant prostates. Br J Cancer 1986;53:547-554. (Pubitemid 16111973)
15. Tsurusaki T, Koji T, Sakai H, et al. Cellular expression of beta-microseminoprotein (beta-MSP) mRNA and its protein in untreated prostate cancer. Prostate 1998;35:109-116. (Pubitemid 28183293)
16. Chan PS, Chan LW, Xuan JW, et al. In situ hybridization study of PSP94 (prostatic secretory protein of 94 amino acids) expression in human prostates. Prostate 1999;41:99-109. (Pubitemid 29446964)
17. Sakai H, Tsurusaki T, Kanda S, et al. Prognostic significance of beta-microseminoprotein mRNA expression in prostate cancer. Prostate 1999;38:278-284. (Pubitemid 29119793)
18. Vanaja DK, Cheville JC, Iturria SJ, et al. Transcriptional silencing of zinc finger protein 185 identified by expression profiling is associated with prostate cancer progression. Cancer Res 2003;63:3877-3882. (Pubitemid 36917897)
19. Reeves JR, Dulude H, Panchal C, et al. Prognostic value of prostate secretory protein of 94 amino acids and its binding protein after radical prostatectomy. Clin Cancer Res 2006;12:6018-6022. (Pubitemid 44703763)
20. Thomas G, Jacobs KB, Yeager M, et al. Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet 2008;40:310-315. (Pubitemid 351311773)
21. Eeles RA, Kote-Jarai Z, Giles GG, et al. Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet 2008;40:316-321. (Pubitemid 351311772)
22. Chang BL, Cramer SD, Wiklund F, et al. Fine mapping association study and functional analysis implicate a SNP in MSMB at 10q11 as a causal variant for prostate cancer risk. Hum Mol Genet 2009;18:1368-1375.
23. Lou H, Yeager M, Li H, et al. Fine mapping and functional analysis of a common variant in MSMB on chromosome 10q11.2 associated with prostate cancer susceptibility. Proc Natl Acad Sci USA 2009;106: 7933-7938.
24. Kote-Jarai Z, Leongamornlert D, Tymrakiewicz M, et al. Mutation analysis of the MSMB gene in familial prostate cancer. Br J Cancer 2010;102:414-418.
25. Yeager M, Deng Z, Boland J, et al. Comprehensive resequence analysis of a 97kb region of chromosome 10q11.2 containing the MSMB gene associated with prostate cancer. Hum Genet 2009;126:743-750.
26. Asmann YW, Kosari F, Wang K, et al. Identification of differentially expressed genes in normal and malignant prostate by electronic profiling of expressed sequence tags. Cancer Res 2002;62:3308-3314. (Pubitemid 34602429)
27. Ernst T, Hergenhahn M, Kenzelmann M, et al. Decrease and gain of gene expression are equally discriminatory markers for prostate carcinoma: a gene expression analysis on total and microdissected prostate tissue. Am J Pathol 2002;160:2169-2180. (Pubitemid 34663408)
28. Bjartell A, Johansson R, Bjork T, et al. Immunohisto-chemical detection of cysteine-rich secretory protein 3 in tissue and in serum from men with cancer or benign enlargement of the prostate gland. Prostate 2006;66: 591-603.
29. Kosari F, Asmann YW, Cheville JC, et al. Cysteine-rich secretory protein-3: a potential biomarker for prostate cancer. Cancer Epidemiol Biomarkers Prev 2002;11: 1419-1426. (Pubitemid 35340379)
30. Udby L, Lundwall A, Johnsen AH, et al. beta-Micro-seminoprotein binds CRISP-3 in human seminal plasma. Biochem Biophys Res Commun 2005;333: 555-561. (Pubitemid 40848327)
31. Erbersdobler A, Isbarn H, Steiner I, et al. Predictive value of prostate-specific antigen expression in prostate cancer: a tissue microarray study. Urology 2009;74: 1169-1173.
32. Fleischmann A, Schlomm T, Huland H, et al. Distinct subcellular expression patterns of neutral endopepti-dase (CD10) in prostate cancer predict diverging clinical courses in surgically treated patients. Clin Cancer Res 2008;14:7838-7842.
33. Udby L, Bjartell A, Malm J, et al. Characterization and localization of cysteine-rich secretory protein 3 (CRISP-3) in the human male reproductive tract. J Androl 2005;26:333-342. (Pubitemid 40628969)
34. Abrahamsson PA, Andersson C, Bjork T, et al. Radio-immunoassay of beta-microseminoprotein, a prostatic-secreted protein present in sera of both men and women. Clin Chem 1989;35:1497-1503. (Pubitemid 19187853)
35. Ulmert D, O'Brien MF, Bjartell AS, et al. Prostate kallikrein markers in diagnosis, risk stratification and prognosis. Nat Rev Urol 2009;6:384-391.
36. Garde SV, Basrur VS, Li L, et al. Prostate secretory protein (PSP94) suppresses the growth of androgen-independent prostate cancer cell line (PC3) and xenografts by inducing apoptosis. Prostate 1999;38: 118-125. (Pubitemid 29052950)
37. Shukeir N, Arakelian A, Kadhim S, et al. Prostate secretory protein PSP-94 decreases tumor growth and hypercalcemia of malignancy in a syngenic in vivo model of prostate cancer. Cancer Res 2003;63: 2072-2078. (Pubitemid 36546186)
38. Garde S, Fraser JE, Nematpoor N, et al. Cloning, expression, purification and functional characterization of recombinant human PSP94. Protein Expr Purif 2007;54:193-203. (Pubitemid 46795568)
39. Shukeir N, Arakelian A, Chen G, et al. A synthetic 15-mer peptide (PCK3145) derived from prostate secretory protein can reduce tumor growth, experimental skeletal metastases, and malignancy-associated hypercalce-mia. Cancer Res 2004;64:5370-5377. (Pubitemid 39006558)
40. Annabi B, Bouzeghrane M, Currie JC, et al. A PSP94-derived peptide PCK3145 inhibits MMP-9 secretion and triggers CD44 cell surface shedding: implication in tumor metastasis. Clin Exp Metastasis 2005;22:429-439. (Pubitemid 41609302)
41. Annabi B, Currie JC, Bouzeghrane M, et al. Contribution of the 37-kDa laminin receptor precursor in the anti-metastatic PSP94-derived peptide PCK3145 cell surface binding. Biochem Biophys Res Commun 2006;346:358-366. (Pubitemid 43866006)
42. Lamy S, Ruiz MT, Wisniewski J, et al. A prostate secretory protein94-derived synthetic peptide PCK3145 inhibits VEGF signalling in endothelial cells: implication in tumor angiogenesis. Int J Cancer 2006; 118:2350-2358.
43. Xu B, Wang J, Tong N, et al. A functional polymorphism in MSMB gene promoter is associated with prostate cancer risk and serum MSMB expression. Prostate 2010;70:1146-1152.
44. Beke L, Nuytten M, Van Eynde A, et al. The gene encoding the prostatic tumor suppressor PSP94 is a target for repression by the Polycomb group protein EZH2. Oncogene 2007;26:4590-4595. (Pubitemid 47037047)
45. Varambally S, Dhanasekaran SM, Zhou M, et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002;419:624-629.
46. Dahlman A, Edsjo A, Hallden C, et al. Effect of androgen deprivation therapy on the expression of prostate cancer biomarkers MSMB and MSMB-binding protein CRISP3. Prostate Cancer Prostatic Dis 2010;13: 369-375.
47. Birnie R, Bryce SD, Roome C, et al. Gene expression profiling of human prostate cancer stem cells reveals a pro-inflammatory phenotype and the importance of extracellular matrix interactions. Genome Biol 2008;9:R83.